Reverse merger turns Passage Bio into Remix Therapeutics after FDA blocked PBFT02's path; REM-422 Phase 2 ACC data in 2027 is the new make-or-break event

Passage Bio, a clinical-stage biotech company, is merging into Remix Therapeutics after its lead gene therapy for a rare inherited dementia was rejected by the FDA; the combined entity will focus on REM-422, an mRNA-based cancer drug for adenoid cystic carcinoma that is not yet approved.

Passage Bio, built around PBFT02, a gene therapy for a rare inherited dementia, is being subsumed into Remix Therapeutics via reverse merger after FDA rejected a single-arm registrational path and required a randomized trial the company could not feasibly run. What survives is REM-422, an mRNA degrader in a registrational Phase 2 for adenoid cystic carcinoma, an unproven asset in a new modality with no efficacy data yet disclosed. The thesis now resolves entirely on whether REM-422 generates convincing ACC response data in 2027, with no approved therapies in that setting but an unvalidated mechanism carrying the full weight of the combined company.